Company profile

Liam J. Kelly
Fiscal year end
IRS number

TFX stock data



30 Jul 20
6 Aug 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Jun 20 Mar 20 Dec 19 Sep 19
Revenue 567.03M 630.64M 680.95M 648.32M
Net income 11.46M 131.15M 108.27M 228.93M
Diluted EPS 0.24 2.78 2.29 4.85
Net profit margin 2.02% 20.80% 15.90% 35.31%
Operating income 38.81M 157.09M 126.93M 117.62M
Net change in cash 147.06M 105.39M 43.54M -46.35M
Cash on hand 553.54M 406.48M 301.08M 257.54M
Cost of revenue 288.66M 297.02M 282.69M 272.64M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 2.6B 2.45B 2.15B 1.87B
Net income 461.47M 200.8M 152.53M 237.84M
Diluted EPS 9.8 4.29 3.27 4.98
Net profit margin 17.78% 8.20% 7.11% 12.73%
Operating income 427.25M 321.7M 372.28M 319.45M
Net change in cash -56.08M 23.6M -210.23M 205.42M
Cash on hand 301.08M 357.16M 333.56M 543.79M
Cost of revenue 1.1B 1.06B 974.5M 871.83M

Financial data from Teleflex earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
27 Jul 20 Klasko Stephen K. M.D. Common Stock Sell Dispose S Yes 386.35 200 77.27K 1,120.941
27 Jul 20 Klasko Stephen K. M.D. Common Stock Option exercise Aquire M Yes 58.25 200 11.65K 1,320.941
27 Jul 20 Klasko Stephen K. M.D. Stock Option / Common Stock Option exercise Dispose M Yes 58.25 200 11.65K 600
25 Jun 20 Klasko Stephen K. M.D. Common Stock Grant Dispose A Yes 356.07 200 71.21K 1,120.941
25 Jun 20 Klasko Stephen K. M.D. Common Stock Option exercise Aquire M Yes 58.25 200 11.65K 1,320.941
25 Jun 20 Klasko Stephen K. M.D. Stock Option / Common Stock Option exercise Dispose M Yes 58.25 200 11.65K 800
26 May 20 Klasko Stephen K. M.D. Common Stock Sell Dispose S Yes 375.14 200 75.03K 1,120.941
26 May 20 Klasko Stephen K. M.D. Common Stock Option exercise Aquire M Yes 58.25 200 11.65K 1,320.941
26 May 20 Klasko Stephen K. M.D. Stock Option / Common Stock Option exercise Dispose M Yes 58.25 200 11.65K 1,000
11 May 20 Cameron P Hicks Common Stock Option exercise Aquire M No 101.12 400 40.45K 8,157.02
91.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 502 527 -4.7%
Opened positions 56 75 -25.3%
Closed positions 81 62 +30.6%
Increased positions 165 180 -8.3%
Reduced positions 189 174 +8.6%
13F shares
Current Prev Q Change
Total value 315.9B 417.57B -24.3%
Total shares 42.32M 42.58M -0.6%
Total puts 30K 19.7K +52.3%
Total calls 60.3K 33.7K +78.9%
Total put/call ratio 0.5 0.6 -14.9%
Largest owners
Shares Value Change
N Price T Rowe Associates 5.4M $1.58B -0.1%
Vanguard 5.24M $1.53B +2.3%
BLK BlackRock 4.65M $1.36B +8.3%
Atlanta Capital Management Co L L C 2M $585.78M -7.5%
STT State Street 1.91M $560.82M +0.4%
American Century Companies 1.32M $385.33M +21.3%
Wellington Management 1.23M $360.53M -8.9%
IVZ Invesco 1.05M $308.54M -8.8%
JHG Janus Henderson 813.76K $238.32M -10.0%
Geode Capital Management 706.56K $206.51M -2.5%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -423K EXIT
BLK BlackRock 4.65M +357.88K +8.3%
Marshall Wace 417.99K -308.69K -42.5%
GQG Partners 303.59K +272.27K +869.2%
American Century Companies 1.32M +231K +21.3%
Copper Rock Capital Partners 227.98K +227.98K NEW
GS Goldman Sachs 380.7K -194.14K -33.8%
Citadel Advisors 291.78K +164.61K +129.4%
Atlanta Capital Management Co L L C 2M -162.08K -7.5%
Scout Investments 70.32K -120.52K -63.2%

Financial report summary

Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Teleflex Incorporated (“we,” “us,” “our" and “Teleflex”) is a global provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.
  • We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not meet our objectives. In addition, we may seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, particularly in Asia, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel.
Content analysis ?
H.S. senior Avg
New words: advantage, Attorney, back, began, broadly, CID, civil, committed, constant, contractual, coupled, deadline, declining, Default, Department, DOJ, downgrade, driven, entertainment, False, fewer, floating, half, holder, IRS, Justice, matter, Northern, offered, offering, opportunity, penalty, premium, private, progressed, promote, qualification, rebate, refined, shift, sought, spread, Statute, sum, temporary, timeline, Treasury, trend, unconditionally, validation, weekly, yield
Removed: apply, April, relate


Guidewire capture
4 Aug 20
Assemblies and methods for capturing a guidewire advanced through a blood vessel in a retrograde direction are disclosed.
Apparatus for Accessing Bone Marrow Including Depth Control Mechanism
30 Jul 20
An apparatus for accessing bone marrow inside a bone is provided.
Endoscopy device
28 Jul 20
An endoscopy device (1) for facilitating use of an endoscope, comprising at least one airway tube (2) and a mask (3) having a distal end (4), a proximal end (5) and a peripheral formation ξβ) capable of conforming to, and fitting within, the actual and potential space behind the larynx of the patient to form a seal around the circumference of the laryngeal inlet, the peripheral formation (6) establishing separation between a laryngeal; chamber side (3a) and a pharyngeal side (3b), the device further comprising a conduit (8) adapted for passage of an endoscope into the oesophagus of a patient when mask (3) is in place, conduit (8) including a distal end for cooperation with the oesophageal sphincter, the conduit having a laryngeal side (8d), a pharyngeal side (8c), a right side (8e) and a left side (8f), and an outlet wherein at the outlet the width between the left side and the right side is smaller than the width of the conduit.
Closure device for sealing percutaneous opening in a vessel
28 Jul 20
Closure systems, kits and methods for sealing a percutaneous puncture or other opening in a blood vessel wall, body cavity or biopsy tract are disclosed.
Subintimal catheter device, assembly and related methods
28 Jul 20
Catheter devices, assemblies and related methods for percutaneous crossing of an occlusion in a blood vessel are disclosed.